Related references
Note: Only part of the references are listed.Risk factors for inhibitor development in severe hemophilia a
Isabella Garagiola et al.
THROMBOSIS RESEARCH (2018)
Product type and other environmental risk factors for inhibitor development in severe hemophilia A
Flora Peyvandi et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)
Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A
Antonino Cannavo et al.
BLOOD (2017)
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
F. Peyvandi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Appearance of High-Affinity Antibodies Precedes Clinical Diagnosis of FVIII Inhibitors - Preliminary Analysis from the Hemophilia Inhibitor PUP Study (HIPS)
Birgit M. Reipert et al.
BLOOD (2016)
Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans
Christoph J. Hofbauer et al.
BLOOD (2015)
Toward optimal therapy for inhibitors in hemophilia
Christine L. Kempton et al.
BLOOD (2014)
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients
Shawn F. J. Whelan et al.
BLOOD (2013)
Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX
P Lollar
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99
SC Darby et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Environmental and genetic factors influencing inhibitor development
J Oldenburg et al.
SEMINARS IN HEMATOLOGY (2004)
Share Paper
